UBS AM
SLS icon

UBS AM’s SELLAS Life Sciences SLS Stock Holding History

UBS AM’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.04M Buy
+273,403
New +$1.89M ﹤0.01% 1709

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AFM
Anson Funds Management Dallas, Texas $1.68B AUM 373.57% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Jones Financial Companies
Jones Financial Companies Des Peres, Missouri $250B AUM 21.32% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

UBS AM's SLS Position: Q2 2026 in Review

UBS AM opened a new position in SELLAS Life Sciences (SLS) in Q2 2026: 273,403 shares worth $4.04M. The stake represents ﹤0.01% of the portfolio and ranks #1709 among its holdings.

192 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • UBS AM held 273,403 shares of SELLAS Life Sciences worth $4.04M as of Q2 2026.
  • SELLAS Life Sciences was a new UBS AM position in Q2 2026.
  • SELLAS Life Sciences made up ﹤0.01% of UBS AM's portfolio in Q2 2026, its #1709 holding.
  • 192 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.